Study reports, policy statements, and expert opinion provide information on medical communications and health economic issues we face today.

Sources vary and include government, industry, academia, and professional organizations. The cost and benefit of new drugs and the role of direct to advertising are chief topics discussed.

PRESS RELEASES:

DOJ URGED TO REMOVE FDCA OVERSIGHT
FROM OFFICE OF CONSUMER LITIGATION

COALITION URGES FDA TO STRENGTHEN DTC ADVERTISING BY PREVENTING "INFORMATION OVERLOAD"

Drug Industry Response to Time Magazine Article

COALITION ACTIONS:

Coalition for Healthcare Communication Announces Favorable Results of Advertising Program Aimed at Increasing Physician Awareness of Rx Patient Assistance Programs
July, 2004

Coalition Response to FDA Request for DTC Comments
(Includes introduction by Jack E. Angel, Coalition Executive Director, and (Part 1) white paper, "Direct-To-Consumer {DTC} Advertising: A Practical Communications Model and Commentary on Risk Communications" by Dr. Lewis G. Pringle, Chairman of the Department of Managerial Economics and Professor of Marketing, Yorktown University)and (Part 2) "Aligning Risk Communication Mandates with Practical Communication Challenges" by Harry Sweeney
January 14, 2004
PDF Format

Comments to FDA on Internet Regulatory Issues

OTHER HEALTHCARE ISSUES:

WASHINGTON LEGAL FOUNDATION CHALLENGES
DEPARTMENT OF JUSTICE (PDF)
The Washington Legal Foundation urges the Department of Justice to change how it handles Food, Drug and Cosmetic Act cases. WLF cites DOJ failure to provide consistent guidance and oversight; warns of danger to public health by inhibition of free information flow on FDA approved drugs.

FCC SUSPENDS TOUGH, NEW DO-NOT-FAX RULE
RETAINS NEED TO HAVE A BUSINESS RELATIONSHIP

WLF Decision and Its Implications

Review of Standards for Commercial Support of CME

Value of Direct-To-Consumer Advertising